SCHEMBL14320409

SCHEMBL14320409

CN(C)c1ccc(Nc2nc(-c3cccs3)nc3cn[nH]c23)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 12/20 0.66
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
PDE5A O76074 1/20 0.48
KDM4E B2RXH2 3/20 0.47
LMNA P02545 3/20 0.47
MAPT P10636 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HTT P42858 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
GBA1 P04062 1/20 0.47
ABCG2 Q9UNQ0 3/20 0.43
ABCB1 P08183 1/20 0.42
ABCC1 P33527 1/20 0.42
HPGD P15428 2/20 0.41
MAPK1 P28482 2/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14320697 0.85 KDM1A (0.48) KDM1AMEN1KMT2APDE5AKDM4E
SCHEMBL27932744 0.83 MEN1 (0.52) KDM1AMEN1KMT2APDE5AKDM4E
SCHEMBL13737153 0.83 PDE5A (0.48) KDM1AMEN1KMT2APDE5AKDM4E
SCHEMBL14320367 0.82 KDM1A (0.66) KDM1AMEN1KMT2AKDM4ELMNA
SCHEMBL14320689 0.81 KDM4E (0.57) KDM1AMEN1KMT2AKDM4ELMNA
SCHEMBL14320640 0.81 PDE5A (0.46) KDM1AMEN1KMT2APDE5AKDM4E
SCHEMBL14320937 0.81 ABCG2 (0.46) KDM1AMEN1KMT2APDE5AKDM4E
SCHEMBL14320984 0.81 PDE5A (0.44) KDM1AMEN1KMT2APDE5AKDM4E
SCHEMBL14321176 0.81 FLT3 (0.53) KDM1AMEN1KMT2APDE5AKDM4E
SCHEMBL14321028 0.80 PDE5A (0.46) KDM1AMEN1KMT2APDE5AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US claimed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP claimed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US claimed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 US disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK KDM1A 1770/4885MEN1 544/4885KMT2A 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.